Horizon Europe for biotech can provide access to substantial funding, international expertise, specialised infrastructure and strategic partnerships across different stages of research and development. Its relevance, however, depends on whether the project can respond convincingly to a defined European priority and assemble the capabilities required for execution.
Table of Contents
For biotechnology companies, the project’s regulatory trajectory, intended users, implementation model and pathway towards impact must all fit the funding opportunity. Consortium design becomes part of this assessment, since the selected partners will determine whether the proposed work is technically credible and operationally deliverable.
The Horizon Europe Health Work Programme for 2026–2027 places strong emphasis on life sciences, biotechnology, critical health technologies and the development of more resilient healthcare systems. Its topics cover areas ranging from vaccines and advanced therapies to regenerative medicine, biomarkers, diagnostic technologies and clinical trials.
What does Horizon Europe for biotech offer across the development pathway?
Horizon Europe for biotech spans several funding routes, designed for different scientific objectives, collaboration models and levels of maturity. Collaborative opportunities are particularly prominent within the Health Cluster, although relevant funding may also be available through the European Innovation Council (EIC), research infrastructures, European Partnerships, innovation ecosystems and other thematic areas.
Within the main work programmes, the most common types of action include:
- Research and Innovation Actions (RIA): primarily support the generation of new knowledge and the exploration or validation of new technologies, products, processes or solutions;
- Innovation Actions (IA): tend to focus more strongly on prototyping, testing, demonstration, validation and activities closer to deployment;
- Coordination and Support Actions (CSA): support activities such as networking, standardisation, knowledge exchange, communication and coordination, and generally do not fund research and innovation activities.
The 2026–2027 Health Work Programme illustrates this breadth. It includes topics addressing New Approach Methodologies, regenerative medicine, ATMP centres of excellence, clinical trials, AI-supported biomarkers, bioprinting, biological production platforms and point-of-care diagnostics. Each opportunity nevertheless has its own scope, funding conditions and consortium requirements, which must be assessed individually.
How to identify the right funding opportunity in Horizon Europe for biotech projects
A relevant scientific theme provides an initial filter. The decisive assessment concerns whether the project can meet the policy, technical and operational expectations embedded in the call. Applicants should therefore work from the project’s next development milestone towards the most suitable funding route, while testing the fit against the complete topic documentation.
1. Start with the project’s development stage and strategic objective
When assessing Horizon Europe for biotech opportunities, the first step is to define what the project needs to achieve during the proposed funding period. An early discovery platform, a therapeutic candidate entering non-clinical development, a diagnostic tool approaching clinical evaluation and a technology preparing for market validation require different activities, partners and forms of evidence.
Applicants should clarify the current maturity of the technology, the scientific uncertainty that remains, the next development milestone and the resources needed to reach it. They should also determine whether the project requires:
- Collaborative research;
- Infrastructure access;
- Regulatory preparation;
- Clinical validation;
- Manufacturing development;
- Support for later-stage innovation.
2. Analyse the destination, expected outcomes and topic scope
Horizon Europe work programmes are structured around destinations, which describe the wider expected impacts of the programme, and topics, which define the expected outcomes and scope of the individual funding opportunity. A proposal must therefore respond to both the immediate topic requirements and the longer-term policy direction to which it contributes.
The topic analysis should identify:
- The challenge and target groups addressed;
- The expected outcomes to which the results must contribute;
- The activities, technologies or development stages covered by the scope;
- Any required stakeholder, end-user or patient involvement;
- Specific regulatory, ethical, clinical or data-related expectations;
- Cross-cutting requirements, including open science or international cooperation, where relevant.
In Horizon Europe for biotech, this analysis should guide the translation of the work programme into clear objectives, methods, outputs and a realistic implementation plan.
3. Check the type of action, eligibility and funding conditions
The type of action determines the expected balance between research, development, validation and coordination, as well as the applicable funding rate and evaluation requirements. RIA, IA and CSA should therefore be treated as distinct routes. Eligibility must also be verified against the General Annexes and the specific topic conditions, including requirements concerning consortium composition, eligible countries and partner profiles.
When assessing Horizon Europe for biotech, applicants should also review the indicative budget, expected EU contribution, funding model, submission deadline and evaluation procedure. Topic-specific conditions may modify the general rules, particularly regarding international participation, lump-sum funding, clinical studies, strategic technologies and single-stage or two-stage applications.
4. Test whether the project can deliver the expected impact
Scientific merit must be connected to a credible pathway from project results to their intended use. Horizon Europe distinguishes between:
- The results generated during project implementation;
- The medium-term outcomes enabled by the uptake and use of those results;
- The wider scientific, economic or societal impacts expected over time.
For a biotech project, this may involve explaining how experimental evidence will support regulatory decisions, how a platform will be validated by intended users, how a therapeutic candidate will progress towards clinical development or how a diagnostic technology will be integrated into healthcare practice.
The proposal should identify who will use the results, what conditions are required for uptake and how the consortium will address exploitation, dissemination and communication.
How to build a Horizon Europe consortium around the project’s needs
In Horizon Europe for biotech, building a credible consortium starts with identifying the required capabilities, selecting complementary partners and defining responsibilities and governance.
1. Map the capabilities required across the development pathway
The first step is to identify the expertise, infrastructure and resources needed at each stage. Depending on the project, this may include:
- Discovery and translational research;
- Non-clinical or clinical development;
- Regulatory and manufacturing strategy;
- Data management, exploitation and market access.
This helps identify missing expertise and technical dependencies that could affect delivery. Where relevant, patients, healthcare professionals, regulators and other prospective users should also be involved early to support practical relevance and later uptake.
2. Select complementary partners with distinct responsibilities
Each partner should contribute a clearly defined capability, asset, infrastructure or operational function. A consortium may combine biotechnology companies, universities, clinical centres, CROs, manufacturing organisations, patient groups and public bodies, for example.
Partner selection in Horizon Europe for biotech should also consider relevant track record, operational capacity and the ability to contribute within the proposed timeline.
3. Define governance, work packages and interfaces early
Once the core partners have been selected, their contributions should be translated into a clear implementation structure. Early agreement is particularly important regarding:
- Coordination and internal reporting;
- Work package leadership, tasks and dependencies;
- Budget allocation and risk management;
- Intellectual property, data access and exploitation rights.
The budget should reflect the tasks and resources assigned to each partner. These arrangements should subsequently be formalised in a written consortium agreement, unless the specific call conditions provide otherwise.
Supporting biotech consortia from proposal design to execution
A competitive Horizon Europe proposal must connect scientific ambition with a credible development and implementation pathway. This becomes particularly important when the project includes regulated activities, specialised evidence generation, clinical studies or manufacturing requirements.
VectorB2B supports biotechnology companies and research organisations across discovery, non-clinical development, Chemistry, Manufacturing and Controls (CMC), clinical services and R&D project management. This integrated perspective can help consortia identify technical dependencies and connect project outputs to subsequent development milestones.
By contributing specialised execution capacity from proposal design through implementation, VectorB2B can help reinforce the operational foundations of projects developed under Horizon Europe for biotech. Contact our team to discuss how we can support your consortium!
Frequently asked questions (FAQ)
1. How should the consortium translate its capabilities into a competitive proposal?
Each partner’s expertise should be connected to specific tasks, resources, deliverables and responsibilities. The proposal must demonstrate how the consortium addresses the three evaluation criteria: “Excellence”, “Impact” and “Quality and efficiency of the implementation”.
2. Which Horizon Europe funding routes are most relevant to biotech companies?
The most suitable Horizon Europe for biotech funding route depends on the project’s maturity and objective. The Health Cluster is particularly relevant to collaborative health research, while European Partnerships, research infrastructures, innovation ecosystems and selected calls in other thematic areas may also provide suitable opportunities. EIC instruments can support certain deep-tech projects, although they follow separate work programmes and conditions.
3. How many partners are required for a Horizon Europe consortium?
Unless the topic specifies otherwise, collaborative actions generally require at least three independent legal entities from three different EU Member States or Associated Countries, including at least one from an EU Member State. As requirements may vary, applicants should always check the specific call conditions.
